Shares of Opiant Pharmaceuticals Inc (NASDAQ:OPNT) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.
Brokerages have set a 12-month consensus target price of $47.00 for the company and are anticipating that the company will post ($0.08) earnings per share for the current quarter, according to Zacks. Zacks has also given Opiant Pharmaceuticals an industry rank of 68 out of 256 based on the ratings given to related companies.
Separately, Cantor Fitzgerald set a $42.00 target price on shares of Opiant Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, October 4th.
Shares of NASDAQ OPNT traded down $0.84 during mid-day trading on Thursday, hitting $13.61. 11,797 shares of the company’s stock traded hands, compared to its average volume of 13,899. The stock has a market capitalization of $55.41 million, a price-to-earnings ratio of 4.66 and a beta of 0.69. Opiant Pharmaceuticals has a 1 year low of $12.02 and a 1 year high of $32.28.
Opiant Pharmaceuticals (NASDAQ:OPNT) last announced its earnings results on Wednesday, November 7th. The technology company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.21). The business had revenue of $4.37 million for the quarter, compared to analysts’ expectations of $4.70 million. Opiant Pharmaceuticals had a negative net margin of 187.13% and a negative return on equity of 175.03%. On average, equities analysts forecast that Opiant Pharmaceuticals will post -4.59 EPS for the current fiscal year.
In other news, CEO Roger Crystal sold 10,847 shares of the company’s stock in a transaction dated Tuesday, October 9th. The shares were sold at an average price of $17.21, for a total transaction of $186,676.87. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Phil Skolnick sold 4,321 shares of the company’s stock in a transaction dated Thursday, December 6th. The shares were sold at an average price of $16.06, for a total transaction of $69,395.26. The disclosure for this sale can be found here. Insiders have sold a total of 16,989 shares of company stock worth $288,868 over the last 90 days. Corporate insiders own 37.92% of the company’s stock.
A number of large investors have recently modified their holdings of OPNT. Northern Trust Corp bought a new position in Opiant Pharmaceuticals during the 2nd quarter valued at about $350,000. Brasada Capital Management LP bought a new position in Opiant Pharmaceuticals during the 3rd quarter valued at about $268,000. Granite Point Capital Management L.P. bought a new position in Opiant Pharmaceuticals during the 3rd quarter valued at about $1,340,000. Stonepine Capital Management LLC bought a new position in Opiant Pharmaceuticals during the 3rd quarter valued at about $3,320,000. Finally, Vanguard Group Inc. grew its holdings in Opiant Pharmaceuticals by 25.1% during the 3rd quarter. Vanguard Group Inc. now owns 105,432 shares of the technology company’s stock valued at $1,883,000 after purchasing an additional 21,151 shares during the last quarter. Institutional investors own 17.01% of the company’s stock.
About Opiant Pharmaceuticals
Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.
See Also: What is the Dividend Aristocrat Index?
Get a free copy of the Zacks research report on Opiant Pharmaceuticals (OPNT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com